 |
|
 |
- May 17, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Update on Dietary and Drug Management of Atherogenic Dyslipidemia of the Insulin Resistance Syndrome"Dr. Ronald M. Krauss (biography)
English - 2005-11-13 - 61 minutes
|
 | (38 slides) |
Summary :
In this presentation Dr. Krauss talks about treatment options that are available for the management of the atherogenic dyslipidemia associated with insulin resistance.
This atherogenic dyslipidemia is characterised by high triglycerides, low HDL cholesterol and an increase in small dense LDL particles. Although pharmacological treatments are available to address these abnormalities, Dr. Krauss recalls attention to the importance of lifestyle modifications. Various dietary weight loss programs, for example have been shown to improve lipid parameters, however adherence to the diet is an important determining factor for outcomes (1). In the Diabetes Prevention Program, intensive lifestyle modification including diet and exercise was also shown to improve lipid parameters and other components of the metabolic syndrome (2).
Pharmacologic options for managing atherogenic dyslipidemia are the LDL-lowering drugs, for example statins, and the triglyceride-reducing, HDL-raising drugs such as niacin and fibrates. Dr. Krauss shows how these treatments impact on triglycerides, HDL cholesterol and LDL particle size, when used alone or in combination, in different patient groups including those with type 2 diabetes. Finally, the lipid effects of the insulin-sensitizing glitazone drugs are briefly discussed, and Dr. Krauss ends by talking about current guidelines for the management of atherogenic dyslipidemia of metabolic syndrome.
Copyright © 2006 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- The nature of atherogenic dyslipidemia associated with insulin resistance
- Effects of diet and exercise on dyslipidemia
- Effects on triglycerides, HDL cholesterol and LDL particle size due to treatment with statins, niacin, fibrates and glitazones
Bibliographic references :
1. Michael L. Dansinger, MD; Joi Augustin Gleason, MS, RD; John L. Griffith, PhD; Harry P. Selker, MD, MSPH; Ernst J. Schaefer, MD. Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for Weight Loss and Heart Disease Risk Reduction: A Randomized Trial JAMA. 2005;293:43-53.
2. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005 Apr 19;142(8):611-9.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
